Journal Scans
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
Pyridoxine Does Not Prevent Capecitabine-Associated Hand-Foot Syndrome
YK Kang, SS Lee, DH Yoon, SY Lee, YJ Chun, MS Kim, M-H Ryu, H-M Chang, J-L Lee, TW Kim
20100606
2010 Jul 6
J Clin Oncol
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
J Clin Oncol. 2010 Jul 6;[Epub Ahead of Print], YK Kang, SS Lee, DH Yoon, SY Lee, YJ Chun, MS Kim, M-H Ryu, H-M Chang, J-L Lee, TW Kim
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Hand-foot syndrome (HFS), a dermatologic reaction on the palms of the hand and/or the soles of the feet, is the most common adverse effect of capecitabine-containing chemotherapy regimens, occurring in 45% to 68% of patients. Although not life threatening, HFS can be serious, resulting in therapy delays or discontinuation. HSF resembles a rat disease (acrodynia) caused by pyridoxine deficiency. This finding formed the basis for the empiric use of pyridoxine to prevent and treat HSF, but reports of...
